肿瘤细胞治疗研究
英文原题：Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.
我们考察了 2022 年接受治疗的患者在各国的治疗率和中心密度；689 个中心报告了 46,143 例 HCT（19,011 例（41.2%）异基因，27,132 例（58.8%）自体）。
本研究分析了2022年各国患者的治疗率和治疗中心密度。当年689个中心报告实施了46,143例造血细胞移植（HCT），其中19,011例（41.2%）为异基因移植，27,132例（58.8%）为自体移植。共有4,329例患者接受先进细胞疗法，其中3,205例接受CAR-T治疗。研究发现，各国自体、异基因HCT的使用情况存在显著差异，CAR-T治疗差异更为明显。研究还展示了不同移植类型以及异基因HCT供者类型和疾病适应证方面的差异。例如，每千万人口中使用无关供者移植率最高的国家为德国（297例）和荷兰（230例）；同胞相合移植率最高的是以色列（148例）和黎巴嫩（113例）；单倍体相合移植率最高的是以色列（94例）和意大利（94例）；脐带血移植率最高的是荷兰（24例）和英国（15例）。研究还考察了异基因HCT用于特定适应证的情况，包括AML首次完全缓解期、骨髓增生异常综合征、骨髓增殖性肿瘤及骨髓衰竭，并分析治疗率与国民总收入（GNI）和人口年龄结构的关系，显示HCT、CAR-T使用率与中心密度之间存在关联；异基因和自体HCT中心密度以意大利最高，CAR-T中心密度以瑞士最高。资源受限国家往往将HCT集中在少数中心。这些数据有助于开展国家间比较。
We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization of autologous, allogeneic HCT and more so for CAR-T. Differences in procedure type and for allogeneic HCT in donor use and disease indication are highlighted. For instance, countries with the highest use of unrelated donors per 10 million inhabitants were Germany (297) and the Netherlands (230), for identical sibling HCT it was Israel (148) and Lebanon (113), for haploidentical it was Israel (94) and Italy (94) and for cord blood it was the Netherlands (24) and the United Kingdom (15). We looked at HCT use for specific indications in allogeneic HCT (AML CR1, MDS, MPN and BMF). We correlated treatment rates with GNI and with demographic age structure and show correlations in HCT and CAR-T use and center density, highest in Italy for allogeneic and autologous HCT and in Switzerland for CAR-T. Resource restricted countries tend to concentrate HCT use in a limited number of centers. These data are useful for comparisons across countries.
MEMBER ACCOUNT
登录成功会直接打开下一页。
